Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception
This study has been completed.
Sponsor:
HRA Pharma
Information provided by:
HRA Pharma
ClinicalTrials.gov Identifier:
NCT00551616
First received: October 30, 2007
Last updated: June 16, 2010
Last verified: June 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to assess the safety and efficacy of CDB-2914 in comparison to levonorgestrel for preventing pregnancy up to 5 days after unprotected sexual intercourse.
| Condition | Intervention | Phase |
|---|---|---|
|
Contraception |
Drug: CDB-2914 Drug: Levonorgestrel |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by HRA Pharma:
Primary Outcome Measures:
- Pregnancy rate
Secondary Outcome Measures:
- Prevented fraction (number of prevented pregnancies divided by number of expected pregnancies)
- Menstrual bleeding patterns
- Frequencies of subjects with treatment emergent adverse events
| Enrollment: | 2321 |
| Study Start Date: | April 2007 |
| Study Completion Date: | April 2009 |
| Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 |
Drug: CDB-2914
Single dose
|
| Active Comparator: 2 |
Drug: Levonorgestrel
Single dose
|
Eligibility| Ages Eligible for Study: | 16 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- women 16 or older in UK(except Northern Ireland) sites, 17 years or more in Northern Ireland (UK) and 18 years or more in Ireland and US
- present within 120 hours of unprotected intercourse
- regular menstrual cycles
- No current use of hormonal contraception
- Willing to not use hormonal methods of contraception until study completion
- At least one complete menstrual cycle (2 menses) post miscarriage, delivery or abortion
- For women who present more than 72 hours after intercourse, decline the insertion of an IUD for emergency contraception
- Able to provide informed consent
- Willing to abstain from further acts of unprotected intercourse until study completion
Exclusion Criteria:
- One or more acts of unprotected intercourse more than 120 hours
- current or recent use of hormonal methods of contraception
- currently pregnant or breastfeeding
- tubal ligation or current use of IUD
- Use of hormonal emergency contraception since last menstrual period
- Current use of IUD
- Tubal ligation
- Partner with a vasectomy
- Unsure about the date of the last menstrual period
- Severe asthma insufficiently controlled by oral glucocorticoid
- Hypersensitivity to the active substance levonorgestrel or any of the excipients of the drug products used in the study
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00551616
Locations
| United States, California | |
| Planned Parenthood Hollywood | |
| Los Angeles, California, United States | |
| Planned Parenthood Santa Monica | |
| Santa Monica, California, United States | |
| United States, Colorado | |
| Planned Parenthood of the Rocky Mountains | |
| Boulder, Colorado, United States | |
| Planned Parenthood of the Rocky Mountains | |
| Denver, Colorado, United States | |
| Planned Parenthood of the Rocky Mountains | |
| Littleton, Colorado, United States | |
| United States, Florida | |
| Planned Parenthood of Greater Miami | |
| Lake Worth, Florida, United States | |
| Planned Parenthood of Greater Miami | |
| Miami, Florida, United States | |
| Planned Parenthood of Greater Miami | |
| North Miami, Florida, United States | |
| Planned Parenthood of Greater Miami | |
| Stuart, Florida, United States | |
| Planned Parenthood of Greater Miami | |
| West Palm Beach, Florida, United States | |
| United States, Ohio | |
| Planned Parenthood of Northeast Ohio Akron Health Center | |
| Akron, Ohio, United States | |
| Planned Parenthood of Northeast Ohio Bedford Health Center | |
| Bedford, Ohio, United States | |
| Planned Parenthood of Northeast Ohio East Cleveland Health Center | |
| Cleveland, Ohio, United States | |
| Planned Parenthood of Northeast Ohio Old Brooklyn Health Center | |
| Cleveland, Ohio, United States | |
| Planned Parenthood of Northeast Ohio Kent Health Center | |
| Kent, Ohio, United States | |
| Planned Parenthood of Northeast Ohio Rocky River Health Center | |
| Rocky River, Ohio, United States | |
| United States, Texas | |
| Planned Parenthood of Texas Capitol Region | |
| Austin, Texas, United States | |
| Planned Parenthood of Houston and Southeast Texas Research Department | |
| Houston, Texas, United States | |
| Fannin Health Center | |
| Houston, Texas, United States | |
| United States, Utah | |
| Planned Parenthood Association of Utah | |
| Ogden, Utah, United States | |
| Planned Parenthood Association of Utah | |
| Orem, Utah, United States | |
| Planned Parenthood Association of Utah | |
| Salt Lake City, Utah, United States | |
| Planned Parenthood Association of Utah | |
| West Valley City, Utah, United States | |
| Ireland | |
| Well Woman Centre | |
| Dublin, Ireland | |
| United Kingdom | |
| NHS Grampian Sexual and Reproductive Health | |
| Aberdeen, United Kingdom | |
| Brook Family Planning Clinic | |
| Belfast, United Kingdom | |
| NHS Lothian Family Planning Service | |
| Edinburgh, United Kingdom | |
| NHS Greater Glasgow & Clyde Family Planning Service | |
| Glasgow, United Kingdom | |
| Liverpool PCT Family Planning Services | |
| Liverpool, United Kingdom | |
| London Sexual and Reproductive Health | |
| London, United Kingdom | |
| Manchester Primary Care Trust | |
| Manchester, United Kingdom | |
| Nottingham Contraception & Sexual Health Service | |
| Nottingham, United Kingdom | |
| Oxfordshire PCT Community Health | |
| Oxford, United Kingdom | |
Sponsors and Collaborators
HRA Pharma
Investigators
| Principal Investigator: | Anna F Glasier, MD | NHS Lothian Family Planning Service |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00551616 History of Changes |
| Other Study ID Numbers: | 2914-004 |
| Study First Received: | October 30, 2007 |
| Last Updated: | June 16, 2010 |
| Health Authority: | United States: Food and Drug Administration United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Additional relevant MeSH terms:
|
Levonorgestrel Contraceptive Agents, Female Contraceptive Agents Reproductive Control Agents Physiological Effects of Drugs |
Pharmacologic Actions Therapeutic Uses Contraceptives, Oral, Synthetic Contraceptives, Oral |
ClinicalTrials.gov processed this record on May 16, 2013